Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy.
While targeting VEGF has shown success against a number of human cancers, drug resistance has resulted in compromised clinical benefits. In this issue of Cancer Cell, Crawford et al. (2009) report that tumors resistant to anti-VEGF therapy stimulate tumor-associated fibroblasts to express proangiogenic PDGF-C, implicating it as a potential therapeutic target.
Francia
Giulio
G
Division of Molecular and Cellular Biology Research, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. francia@swri.ca
Emmenegger
Urban
U
Kerbel
Robert S
RS
D000906:Antibodies / Q000276:immunology / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005347:Fibroblasts / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007167:Immunotherapy; D008222:Lymphokines / Q000378:metabolism; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000276:immunology* / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D010982:Platelet-Derived Growth Factor / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology*
D000906:Antibodies; D008222:Lymphokines; D010982:Platelet-Derived Growth Factor; D042461:Vascular Endothelial Growth Factor A; C411423:platelet-derived growth factor C